A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the efficacy and safety of spartalizumab in patients with refractory esophageal squamous cell carcinoma (ESCC). Patients with histo...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, Yun-Gyoo Lee, Su-Jin Shin, Beung-Chul Ahn, Sung Sook Lee, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Taylor & Francis Group 2024-12-01
Serie:	OncoImmunology
Ämnen:	CD20-positive immune cell Esophageal squamous cell carcinoma immune checkpoint inhibitor PD-L1 expression spartalizumab
Länkar:	https://www.tandfonline.com/doi/10.1080/2162402X.2024.2371563
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!